Database and Biological Material Bank in Obesity Medicine of the Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval)
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 25,000
- 试验地点
- 1
- 主要终点
- Success or failure of obesity medicine interventions
研究概览
简要总结
Obesity medicine, or bariatric medicine, focuses not only on the biological and behavioral aspects, but also on the environmental and social factors that contribute to the development of obesity. Many diseases are associated with obesity, such as type 2 diabetes, hypertension, cardiovascular diseases, numerous cancers, gynecological disorders, etc. Focusing on obesity medicine is crucial for improving patients' quality of life, reducing healthcare costs, and developing effective prevention strategies. The Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval) maintains a clinical database and biological material bank for studying the multidisciplinary management of obesity and its complications.
A biobank is a collection of information, clinical or biochemical data (including radiological, cardiac, and genetic data), and blood samples concerning donors. The information that can be collected includes, for example, age, sex, diagnosis, progression or treatment of a medical condition, medications, DNA, etc. DNA is a molecule present in all cells and contains all the information necessary for the development and functioning of our body.
This bank aims to better characterize patients' profile receiving follow-up care in obesity medicine, identify predictive factors of success or failure of interventions and adapt management strategies according to specific needs. The collected data and blood samples will be used in several research projects with the following objectives:
- To document the socioeconomic, demographic, clinical, radiological, genetic, and biochemical characteristics of patients living with obesity and requiring medical follow-up at the bariatric medicine clinic at the IUCPQ-ULaval
- To explore the effects or associations of genetic and biochemical determinants on health in the context of obesity
- To gain a better understanding of the pathophysiology and genes involved in obesity and associated metabolic abnormalities
- To evaluate the clinical utility of non-invasive biomarkers in the screening of preclinical obesity and its comorbidities and/or
- To evaluate the effectiveness of medications, health behavior changes, and bariatric surgery in order to develop optimal interventions aimed at improving the health and medical management of people with obesity.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To be included in the registry (database + biobank), a person must first be referred to the Bariatric Medicine Clinic at the IUCPQ-ULaval and meet several criteria:
- •Be over 18 years of age
- •Meet at least one of the following five criteria:
- •Body mass index ≥30 kg/m2 with or without comorbidities (preclinical or clinical obesity);
- •Require weight loss related to a transplant, bariatric surgery, or another type of surgery (e.g., hernia repair, orthopedic surgery, neurosurgery, etc.);
- •History of bariatric surgery resulting in weight regain of at least 15% of the total weight lost;
- •History of bariatric surgery resulting in weight loss deemed insufficient by the treating medical team;
- •Having undergone bariatric surgery with complications related to it (i.e., flushing syndrome or hypoglycemia, nephrolithiasis, return of comorbidities in remission, abnormalities in phosphocalcic balance and vitamin deficiencies).
排除标准
- 未提供
研究组 & 干预措施
Obesity medicine cohort
This cohort includes patients followed in bariatric medicine at IUCPQ-ULaval
干预措施: Behavioral and Pharmacological Treatments (Other)
结局指标
主要结局
Success or failure of obesity medicine interventions
时间窗: Baseline to 15-year follow-up. Follow-up is based on standard care consultations which vary from a patient to another
1. Anthropometric Parameters: weight and height combined to obtain BMI (kg/m\^2). Waist circumference (cm); Body composition assessed by bioelectrical impedance analysis 2. Cardiometabolic Parameters and Comorbidities: Hepatic steatosis and fibrosis assessed by controlled attenuation parameter (CAP) and liver stiffness measurement (transient elastography); Liver biochemical parameters (e.g., ALT, AST, GGT); Lipid profile (total cholesterol, LDL-C, HDL-C, triglycerides); Inflammatory markers (as available in medical records); Glycemic parameters (fasting glucose, HbA1c, insulin, as available); Polysomnography parameters (when available); Echocardiographic parameters (when available) 3. Adoption of Lifestyle Intervention: Documented adherence and engagement in prescribed lifestyle interventions, as reported in medical charts 4. Quality of Life: Clinician-documented quality-of-life assessment, as recorded in medical charts 5. Mental Health Parameters: As recorded in medical charts
次要结局
未报告次要终点
研究者
Fannie Lajeunesse-Trempe
Clinician-Researcher
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval